-
Goldman Sachs: Eli Lilly's Shares May Surge By 140% With GLP-1 Drug Boom
Tuesday, December 19, 2023 - 1:03am | 580Read More...Eli Lilly and Co. (NYSE:LLY) could witness a 140% surge in its shares, as predicted by Goldman Sachs. The growth is anticipated to be driven by an increased demand for GLP-1 weight loss and diabetes drugs. What Happened: Goldman Sachs’ latest research suggests a bright future for Eli Lilly,...
-
Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'
Friday, December 8, 2023 - 5:07pm | 751Read More...Congressman Bernie Sanders (I-Vt.) has been known to tussle with public companies over their high prices or anticompetitive behavior, including pharmaceutical companies and their high costs. In his newest battle, Sanders is taking on the growing popularity of weight-loss drugs and diabetes...
-
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
Monday, December 4, 2023 - 9:24pm | 645Read More...What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administered for diabetes and obesity treatment. As reported by CNBC, investors initially expressed concerns about these drugs’ market impact. However, with...
